2026

• patent2026/05/13

  AskAt Secures New U.S. Patent for AAT-730 Salt & Crystal Forms

  AskAt received an Issue Notification dated April 22, 2026 from the U.S. Patent and Trademark Office (USPTO) for a salt and crystal forms patent for its CB2 agonist, AAT-730 (Patent Number: 12,617,776). The notice was issued in connection with US Patent Application No. 18/595,742 (Filing Date: November 11, 2021), which stems from a continuation application for US Patent Application No. 18/035,195. In addition to our granted U.S. patent for a salt and crystal forms of AAT-730 (Patent Number:11,964,963), this approval further solidifies our IP position for AAT-730 in the U.S.

• ir2026/03/23

  13th period financial statement release

  13th period financial statement release

• business2026/02/16

  AskAt Terminates AAT-730 License Agreement Due to Breach by Oxford Cannabinoid Technologies Ltd.

  AskAt Inc. (Headquarters: Nagoya; President: Akihiro Furuta) announced today that it has terminated its license agreement with Oxford Cannabinoid Technologies Ltd. (“OCT”) regarding AAT-730, a CB2 agonist.
  The agreement, originally signed in September 2019, was terminated by AskAt due to a breach of contract by OCT.
  We will seek a new partner to continue the development.